How to Enhance Diagnosis in Fabry Disease: The Power of Information
Abstract
1. Introduction
2. Materials and Methods
2.1. Educational Intervention on FD
- Theoretical phase: this phase was based on 3 online, interactive lessons on FD, performed over one month (each of them lasting 3 h), aimed at raising the disease awareness. More specifically, the topics of the webinars were the following:
- -
- Lesson n. 1: Molecular genetics, epidemiology, clinical presentation, diagnostic work-up and screening and multiorgan involvement.
- -
- Lesson n. 2: Electrocardiographic, echocardiographic, and cardiac magnetic resonance (CMR) characteristics of Fabry cardiomyopathy and its pharmacological management (specific and support therapy).
- -
- Lesson n. 3: Differential diagnosis of Fabry cardiomyopathy with HCM and other HCM phenocopies.
- Tutored phase: Cardiologists have been supported in their daily clinical practice for 5 months. An expert cardiologist from the promotor institution (“Tutor”) was available by video calls for 6 h/5 days a week. They provided interpretative assistance on electrocardiograms (ECG) and echocardiograms when requested and supported the diagnostic work-up of suspected FD cases.
2.2. Active Phase of the Study
- -
- Patients with LVH of unknown etiology (diagnosed in or after the 3rd decade of life) defined by a left ventricular maximum wall thickness (LVMWT) ≥ 13 mm measured on echocardiography or CMR, in absence of male-to-male transmission and co-existent pathologies that could explain the increased LV wall thickness (hypertension, aortic stenosis);
- -
- Patients with LVH (diagnosed in or after the 3rd decade of life) and ECG findings frequently encountered with Fabry cardiomyopathy (short PR interval, right bundle branch block [RBBB], high QRS voltage and remarkable repolarization abnormalities);
- -
- Patients with unexplained LVH (diagnosed in or after the 3rd decade of life) and history of chronic kidney disease (CKD), ischemic stroke or clinical characteristics compatible with FD systemic involvement.
2.3. Diagnostic Kits
2.4. Study Endpoint
3. Results
3.1. Screened Population
3.2. New Diagnosis of Fabry Disease
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
FD | Fabry disease |
CKD | Chronic kidney disease |
GLA | Galactosidase alpha |
HCM | Hypertrophic cardiomyopathy |
LVMWT | Left ventricular maximum wall thickness |
LVH | Left ventricular hypertrophy |
References
- Linhart, A.; Elliott, P.M. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007, 93, 528–535. [Google Scholar] [CrossRef] [PubMed]
- O’Mahony, C.; Elliott, P. Anderson-Fabry disease and the heart. Prog. Cardiovasc. Dis. 2010, 52, 326–335. [Google Scholar] [CrossRef]
- Pieroni, M.; Moon, J.C.; Arbustini, E.; Barriales-Villa, R.; Camporeale, A.; Vujkovac, A.C.; Elliott, P.M.; Hagege, A.; Kuusisto, J.; Linhart, A.; et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2021, 77, 922–936. [Google Scholar] [CrossRef]
- Sunder-Plassmann, G.; Fodinger, M. Diagnosis of Fabry disease: The role of screening and case-finding studies. In Fabry Disease:Perspectives from 5 Years of FOS; Mehta, A., Beck, M., Sunder-Plassmann, G., Eds.; Oxford PharmaGenesis: Oxford, UK, 2006; Chapter 17. [Google Scholar]
- Spada, M.; Pagliardini, S.; Yasuda, M.; Tukel, T.; Thiagarajan, G.; Sakuraba, H.; Ponzone, A.; Desnick, R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 2006, 79, 31–40. [Google Scholar] [CrossRef]
- Hsu, T.R.; Hung, S.C.; Chang, F.P.; Yu, W.C.; Sung, S.H.; Hsu, C.L.; Dzhagalov, I.; Yang, C.F.; Chu, T.H.; Lee, H.J.; et al. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation. J. Am. Coll. Cardiol. 2016, 68, 2554–2563. [Google Scholar] [CrossRef] [PubMed]
- Reisin, R.; Perrin, A.; García-Pavía, P. Time delays in the diagnosis and treatment of Fabry disease. Int. J. Clin. Pract. 2017, 71, e12914. [Google Scholar] [CrossRef] [PubMed]
- Weidemann, F.; Niemann, M.; Breunig, F.; Herrmann, S.; Beer, M.; Störk, S.; Voelker, W.; Ertl, G.; Wanner, C.; Strotmann, J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 2009, 119, 524–529. [Google Scholar] [CrossRef] [PubMed]
- Arends, M.; Wijburg, F.A.; Wanner, C.; Vaz, F.M.; van Kuilenburg, A.B.; Hughes, D.A.; Biegstraaten, M.; Mehta, A.; Hollak, C.E.; Langeveld, M. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol. Genet. Metab. 2017, 121, 157–161. [Google Scholar] [CrossRef]
- Germain, D.P.; Elliott, P.M.; Falissard, B.; Fomin, V.V.; Hilz, M.J.; Jovanovic, A.; Kantola, I.; Linhart, A.; Mignani, R.; Namdar, M.; et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol. Genet. Metab. Rep. 2019, 19, 100454. [Google Scholar] [CrossRef]
- Pieroni, M.; Namdar, M.; Olivotto, I.; Desnick, R.J. Anderson-Fabry disease management: Role of the cardiologist. Eur. Heart J. 2024, 45, 1395–1409. [Google Scholar] [CrossRef]
- Savary, A.L.; Morello, R.; Brasse-Lagnel, C.; Milliez, P.; Bekri, S.; Labombarda, F. Enhancing the diagnosis of fabry disease in cardiology with a targeted information: A before-after control- impact study. Open Heart 2017, 4, e000567. [Google Scholar] [CrossRef]
- Thomas, A.S.; Mehta, A.B. Difficulties and barriers in diagnosing Fabry disease: What can be learnt from the literature? Expert. Opin. Med. Diagn. 2013, 7, 589–599. [Google Scholar] [CrossRef]
- Biegstraaten, M.; Arngrímsson, R.; Barbey, F.; Boks, L.; Cecchi, F.; Deegan, P.B.; Feldt-Rasmussen, U.; Geberhiwot, T.; Germain, D.P.; Hendriksz, C.; et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. Orphanet J. Rare Dis. 2015, 10, 36. [Google Scholar] [CrossRef]
- Meucci, M.C.; Lillo, R.; Del Franco, A.; Monda, E.; Iannaccone, G.; Baldassarre, R.; Di Nicola, F.; Parisi, V.; Lombardo, A.; Spinelli, L.; et al. Prognostic Implications of the Extent of Cardiac Damage in Patients With Fabry Disease. J. Am. Coll. Cardiol. 2023, 82, 1524–1534. [Google Scholar] [CrossRef] [PubMed]
- Del Franco, A.; Iannaccone, G.; Meucci, M.C.; Lillo, R.; Cappelli, F.; Zocchi, C.; Pieroni, M.; Graziani, F.; Olivotto, I. Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal. Heart Fail. Rev. 2024, 29, 431–444. [Google Scholar] [CrossRef]
- Linhart, A.; Kampmann, C.; Zamorano, J.L.; Sunder-Plassmann, G.; Beck, M.; Mehta, A.; Elliott, P.M. European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry Outcome Survey. Eur. Heart J. 2007, 28, 1228–1235. [Google Scholar] [CrossRef]
- Arbelo, E.; Protonotarios, A.; Gimeno, J.R.; Arbustini, E.; Barriales-Villa, R.; Basso, C.; Bezzina, C.R.; Biagini, E.; Blom, N.A.; De Boer, R.A.; et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur. Heart J. 2023, 44, 3503–3626. [Google Scholar] [CrossRef] [PubMed]
- Limongelli, G.; Monda, E.; Tramonte, S.; Gragnano, F.; Masarone, D.; Frisso, G.; Esposito, A.; Gravino, R.; Ammendola, E.; Salerno, G.; et al. Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. Int. J. Cardiol. 2020, 299, 186–191. [Google Scholar] [CrossRef]
- Maurizi, N.; Monda, E.; Biagini, E.; Field, E.; Passantino, S.; Dall’Aglio, G.; Fumagalli, C.; Antiochos, P.; Skalidis, I.; Pieroni, M.; et al. Hypertrophic cardiomyopathy: Prevalence of disease-specific red flags. Eur. Heart J. 2025, ehaf026. [Google Scholar] [CrossRef]
- Vitale, G.; Ditaranto, R.; Graziani, F.; Tanini, I.; Camporeale, A.; Lillo, R.; Rubino, M.; Panaioli, E.; Di Nicola, F.; Ferrara, V.; et al. Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart 2022, 108, 54–60. [Google Scholar] [CrossRef] [PubMed]
- Lu, D.Y.; Huang, W.M.; Wang, W.T.; Hung, S.C.; Sung, S.H.; Chen, C.H.; Yang, Y.J.; Niu, D.M.; Yu, W.C. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. Eur. Heart J. Cardiovasc. Imaging 2022, 23, 487–495. [Google Scholar] [CrossRef] [PubMed]
- Meucci, M.C.; Lillo, R.; Lombardo, A.; Lanza, G.A.; Bootsma, M.; Butcher, S.C.; Massetti, M.; Manna, R.; Bax, J.J.; Crea, F.; et al. Comparative analysis of right ventricular strain in Fabry cardiomyopathy and sarcomeric hypertrophic cardiomyopathy. Eur. Heart J. Cardiovasc. Imaging 2023, 24, 542–551. [Google Scholar] [CrossRef]
- Meucci, M.C.; Lillo, R.; Mango, F.; Marsilia, M.; Iannaccone, G.; Tusa, F.; Luigetti, M.; Biagini, E.; Massetti, M.; Lanza, G.A.; et al. Left atrial structural and functional remodelling in Fabry disease and cardiac amyloidosis: A comparative analysis. Int. J. Cardiol. 2024, 402, 131891. [Google Scholar] [CrossRef]
- Sado, D.M.; White, S.K.; Piechnik, S.K.; Banypersad, S.M.; Treibel, T.; Captur, G.; Fontana, M.; Maestrini, V.; Flett, A.S.; Robson, M.D.; et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ. Cardiovasc. Imaging 2013, 6, 392–398. [Google Scholar] [CrossRef]
- Oder, D.; Liu, D.; Hu, K.; Üçeyler, N.; Salinger, T.; Müntze, J.; Lorenz, K.; Kandolf, R.; Gröne, H.J.; Sommer, C.; et al. Alpha-galactosidase A genotype N215S induces a specific cardiac variant of Fabry disease. Circ. Cardiovasc. Genet. 2017, 10, e00169. [Google Scholar] [CrossRef]
- Germain, D.P.; Brand, E.; Burlina, A.; Cecchi, F.; Garman, S.C.; Kempf, J.; Laney, D.A.; Linhart, A.; Marodi, L.; Nicholls, K.; et al. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Mol. Genet. Genom. Med. 2018, 6, 492–503. [Google Scholar] [CrossRef]
- Monserrat, L.; Gimeno-Blanes, J.R.; Marín, F.; Hermida-Prieto, M.; García-Honrubia, A.; Pérez, I.; Fernández, X.; de Nicolas, R.; de la Morena, G.; Payá, E.; et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2007, 50, 2399–2403. [Google Scholar] [CrossRef]
- Elliott, P.; Baker, R.; Pasquale, F.; Quarta, G.; Ebrahim, H.; Mehta, A.B.; Hughes, D.A. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: The European Anderson-Fabry Disease survey. Heart 2011, 97, 1957–1960. [Google Scholar] [CrossRef] [PubMed]
- Chimenti, C.; Pieroni, M.; Morgante, E.; Antuzzi, D.; Russo, A.; Russo, M.A.; Maseri, A.; Frustaci, A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004, 110, 1047–1053. [Google Scholar] [CrossRef] [PubMed]
- Sachdev, B.; Takenaka, T.; Teraguchi, H.; Tei, C.; Lee, P.; McKenna, W.J.; Elliott, P.M. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002, 105, 1407–1411. [Google Scholar] [CrossRef]
Study Population (n = 45) | |
---|---|
Clinical data | |
Age (years) | 61 ± 11 |
Male (n, %) | 37 (82) |
Positive familiar history of HCM (n, %) | 5 (11) |
Hypertension (n, %) | 18 (40) |
CKD (n, %) | 16 (36) |
Ischaemic stroke (n, %) | 4 (9) |
Pacemaker implantation (n, %) | 4 (9) |
Atrial fibrillation (n, %) | 9 (20) |
Ventricular arrhythmia (n, %) | 1 (2) |
ECG | |
PR interval (ms) | 180 (160–209) |
QRS interval (ms) | 100 (90–130) |
RBBB (n, %) | 7 (16) |
LBBB (n, %) | 6 (13) |
Voltage criteria for LVH (n, %) | 16 (36) |
Echocardiography | |
LVMWT (mm) | 16 (13–19) |
LVEDD (mm) | 48 (43–53) |
LVEF (%) | 60 (54–64) |
LAVi (ml/m2) | 39 (30–51) |
E/A ratio | 0.9 (0.7–1.5) |
Mean E/E’ | 12 (7–18) |
RV wall thickness (mm) | 5 (4–7) |
TAPSE (mm) | 21 (19–25) |
PASP (mm) | 32 (25–41) |
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
---|---|---|---|---|
Clinical data | ||||
Age (years) | 70 | 41 | 74 | 56 |
Sex | Male | Female | Female | Male |
Body surface area (m2) | 2.1 | 1.7 | 2.0 | 2.0 |
GLA variant | p. Asn215Ser | p. Arg227Ter | p. Asn215Ser | p. Asn215Ser |
Disease phenotype | Late-onset | Classic | Late-onset | Late-onset |
Positive familiar history of HCM | No | No | Yes | Yes |
Hypertension | Yes | No | Yes | No |
eGFR (mL/min/1.73 m2) | 94 | 63 | 63 | 106 |
CKD | No | No | No | No |
Pacemaker | Yes | No | No | Yes |
Atrial fibrillation | Yes | No | No | Yes |
Ventricular arrhythmia | No | No | No | No |
Ischaemic stroke | No | Yes | No | No |
Cornea verticillata | No | Yes | No | No |
Angiokeratoma | No | No | No | No |
Hypoacusia | No | No | No | No |
Gastrointestinal symptoms | No | No | Yes | No |
Ntpro-BNP (pg/mL) | 3040 | 250 | 630 | 747 |
ECG | ||||
Rhythm | AF | Sinus | Sinus | Sinus |
PR interval (ms) | - | 200 | 162 | 157 |
QRS interval (ms) | 140 | 90 | 144 | 168 |
RBBB | Yes | No | No | Yes |
LBBB | No | No | Yes | No |
Voltage criteria for LVH | No | Yes | No | Yes |
Echocardiography | ||||
IVSd (mm) | 20 | 13 | 14 | 23 |
PWd (mm) | 19 | 11 | 11 | 16 |
LVMWT (mm) | 20 | 14 | 15 | 23 |
LVEDD (mm) | 51 | 47 | 44 | 50 |
LVEF (%) | 56 | 57 | 59 | 45 |
LAVi (mL/m2) | 73 | 37 | 47 | 41 |
E/A ratio | - | 1.7 | 0.5 | - |
Mean E/E’ | 20 | 14 | 9 | 8 |
RV wall thickness (mm) | 9 | 4 | 6 | 6 |
TAPSE (mm) | 15 | 27 | 21 | 14 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Meucci, M.C.; Lillo, R.; Calcagnino, M.; Tocci, G.; Agricola, E.; Biondi, F.; Di Brango, C.; Guido, V.; Parisi, V.; Giordana, F.; et al. How to Enhance Diagnosis in Fabry Disease: The Power of Information. Cardiogenetics 2025, 15, 21. https://doi.org/10.3390/cardiogenetics15030021
Meucci MC, Lillo R, Calcagnino M, Tocci G, Agricola E, Biondi F, Di Brango C, Guido V, Parisi V, Giordana F, et al. How to Enhance Diagnosis in Fabry Disease: The Power of Information. Cardiogenetics. 2025; 15(3):21. https://doi.org/10.3390/cardiogenetics15030021
Chicago/Turabian StyleMeucci, Maria Chiara, Rosa Lillo, Margherita Calcagnino, Giampaolo Tocci, Eustachio Agricola, Federico Biondi, Claudio Di Brango, Vincenzo Guido, Valentina Parisi, Francesca Giordana, and et al. 2025. "How to Enhance Diagnosis in Fabry Disease: The Power of Information" Cardiogenetics 15, no. 3: 21. https://doi.org/10.3390/cardiogenetics15030021
APA StyleMeucci, M. C., Lillo, R., Calcagnino, M., Tocci, G., Agricola, E., Biondi, F., Di Brango, C., Guido, V., Parisi, V., Giordana, F., Melita, V., Lombardi, M., Scardovi, A. B., Truong, L. V. S., Musella, F., di Spigno, F., Matrone, B., Pariggiano, I., Calabrò, P., ... Burzotta, F. (2025). How to Enhance Diagnosis in Fabry Disease: The Power of Information. Cardiogenetics, 15(3), 21. https://doi.org/10.3390/cardiogenetics15030021